About Clinitech Laboratory Limited
Data last updated:
Clinitech Laboratory Limited is a public limited company based in Navi Mumbai, Maharashtra, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 19 March 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L85195MH2010PLC201078. It is a listed company.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹2.28 Cr. It is led by directors including Jagdish Umakant Nayak (Managing Director) and Jyoti Jagdish Nayak (Whole-Time Director).
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Al – 1/545 Sector 16 Airoli Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Maharashtra, India – 400708.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9.49 Cr, a growth of 15.3% compared to the previous year. For the same year it recorded a net profit of ₹43 Lakh (net margin 4.5%) and EBITDA of ₹1 Cr (EBITDA margin 10.5%). The net worth stands at ₹9.25 Cr (up 4.8% YoY). Total assets are valued at ₹10.04 Cr (up 11.2% YoY).
The company has about 13 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Clinitech Laboratory. As per MCA filings, the company has open charges of ₹1.33 Cr and satisfied charges of ₹32 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ctllab.in.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social Media
- Registered AddressAl – 1/545 Sector 16 Airoli Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Maharashtra, India – 400708
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
CIN History of Clinitech Laboratory Limited
Clinitech Laboratory has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85195MH2010PLC201078, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195MH2010PLC201078 | Current |
| U85195MH2010PLC201078 | Previous |
| U85195MH2010PTC201078 | Previous |
Associated Brands with Clinitech Laboratory Limited
Clinitech Laboratory operates one associated brand: Clinitech Laboratory. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pathology lab services are operated through a chain in India. | clinitechlab.com |
Competitors & Alternatives of Clinitech Laboratory Limited
Brands and companies operating in the same space as Clinitech Laboratory Limited include Dr Lal PathLabs, Redcliffe Labs, Metropolis India and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
 Dr Lal PathLabs | Chain of pathology and radiology labs | Gurugram, India | 1949 |
 Redcliffe Labs | Home-based diagnostic tests are booked via an online platform. | Noida, India | 2018 |
 Metropolis India | Diagnostic centers are operated as a nationwide chain. | Mumbai, India | 1981 |
 Orange health | At-home diagnostic tests are booked and collected by phlebotomists. | Bengaluru, India | 2020 |
 Agilus Diagnostics | Leading diagnostic chain providing quality blood test and full body checkup services | Gurugram, India | 1995 |
 Apollo Diagnostics | Provides pathology lab tests, health check packages, and home sample collection. | Hyderabad, India | 2015 |
 Sterling Accuris Diagnostics | Pathology diagnostic services are offered via a chain of labs. | Ahmedabad, India | 2015 |
 Airmed | Provider of a chain of diagnostic labs | Ahmedabad, India | 2016 |
Business Activity of Clinitech Laboratory Limited
The main business activity of Clinitech Laboratory is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Board of Directors of Clinitech Laboratory Limited
Clinitech Laboratory has 6 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ravikant Moreshwar Mhatre Also directs: Tristar Samriddhi Advisory LLP, Shanthala FMCG Products Limited, Shree Osfm E-Mobility Limited and 1 more | Director | 19 Jun 2023 | 3 Years 3 Months | Current |
| Balu Laxman Kumbharkar Also directs: Waradavinayaka Private Limited | Director | 19 Jun 2023 | 3 Years 3 Months | Current |
| Jagdish Umakant Nayak | Managing Director | 19 Mar 2010 | 16 Years 6 Months | Current |
| Ashutosh Jagdish Nayak Also directs: Sine Vibro LLP | Director | 31 Jan 2022 | 4 Years 8 Months | Current |
| Smita Arjun Patil Also directs: Shanthala FMCG Products Limited | Director | 19 Jun 2023 | 3 Years 3 Months | Current |
| Jyoti Jagdish Nayak | Whole-Time Director | 19 Mar 2010 | 16 Years 6 Months | Current |
Financials of Clinitech Laboratory Limited FY 2025-26 filings available
Clinitech Laboratory Limited reported revenue of ₹9.49 Cr (up 15.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Profit before tax | 0.61 | 0.54 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Balance sheet | ||
| Total assets | 10.04 | 9.03 |
| Net worth | 9.25 | 8.83 |
| Total debt | 0.54 | 0.00 |
| Cash & bank | 2.11 | 3.07 |
| Net working capital | 6.23 | 5.65 |
| Cash flow | ||
| Cash from operations | (0.79) | (0.88) |
| Cash from investing | (0.68) | (0.73) |
| Cash from financing | 0.51 | 3.98 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Balance sheet | ||||||
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Net worth | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Cash & bank | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Cash flow | ||||||
| Cash from operations | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Cash from investing | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Cash from financing | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| Other income | 0.19 | 0.23 |
| Total expenses | 8.49 | 7.41 |
| Employee cost | 2.60 | 2.38 |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Depreciation | 0.51 | 0.45 |
| Interest | 0.07 | 0.06 |
| Profit before tax | 0.61 | 0.54 |
| Tax | 0.18 | 0.16 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 2.28 | 2.28 |
| Reserves & surplus | 6.97 | 6.55 |
| Shareholders' funds (net worth) | 9.25 | 8.83 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.54 | 0.00 |
| Unsecured loans | 0.00 | 0.00 |
| Total debt | 0.54 | 0.00 |
| Total liabilities | 10.04 | 9.03 |
| Assets | ||
| Gross block | 5.90 | 5.33 |
| Net block | 2.18 | 2.12 |
| Capital work in progress | 1.25 | 1.01 |
| Investments | 0.07 | 0.07 |
| Inventories | 0.73 | 0.53 |
| Sundry debtors | 1.85 | 1.54 |
| Cash & bank balances | 2.11 | 3.07 |
| Loans & advances | 2.68 | 2.32 |
| Total current assets | 7.37 | 7.46 |
| Total current liabilities | 1.14 | 1.81 |
| Net working capital | 6.23 | 5.65 |
| Total assets | 10.04 | 9.03 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 3.07 | 0.70 |
| Net cash from operating activities | (0.79) | (0.88) |
| Net cash from investing activities | (0.68) | (0.73) |
| Net cash from financing activities | 0.51 | 3.98 |
| Net change in cash | (0.96) | 2.37 |
| Closing cash | 2.11 | 3.07 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +15.3% | - |
| EBITDA growth | +22.0% | - |
| PBT growth | +13.0% | +9997.0% |
| Net income growth | +48.3% | - |
| Profitability & leverage | ||
| Net income margin | +4.5% | +4.6% |
| Return on capital employed | +6.9% | +6.0% |
| Return on net worth | +4.5% | +3.4% |
| Debt / equity | 0.03 | 0.00 |
| Long-term debt / equity | 0.03 | 0.00 |
| Interest cover | 14.29 | 16.22 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.69 | 1.54 |
| Inventory turnover | 15.06 | 15.53 |
| Debtors turnover | 5.60 | 5.34 |
| EPS (₹) | 1.83 | 1.73 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 40.52 | 38.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| Other income | 0.19 | 0.23 | 0.04 | 0.02 | 0.07 | 0.04 |
| Total expenses | 8.48 | 7.41 | 5.40 | 4.99 | 5.32 | 3.72 |
| Employee cost | 2.60 | 2.38 | 1.92 | 1.55 | 1.38 | 0.92 |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Depreciation | 0.51 | 0.45 | 0.44 | 0.45 | 0.38 | 0.25 |
| Interest | 0.07 | 0.06 | 0.09 | 0.07 | 0.06 | 0.08 |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Tax | 0.18 | 0.16 | 0.13 | 0.25 | 0.19 | 0.14 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 2.28 | 2.28 | 1.68 | 1.50 | 1.50 | 0.67 |
| Reserves & surplus | 6.97 | 6.55 | 1.87 | 0.88 | 0.35 | 0.72 |
| Shareholders' funds (net worth) | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Secured loans | 0.36 | 0.00 | 0.53 | 0.59 | 0.64 | 0.48 |
| Unsecured loans | 0.00 | 0.00 | 0.34 | 0.44 | 0.25 | 0.06 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Total liabilities | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Assets | ||||||
| Gross block | 5.90 | 5.33 | 4.47 | 3.65 | 3.52 | 2.45 |
| Net block | 2.18 | 2.12 | 1.71 | 1.33 | 1.65 | 0.84 |
| Capital work in progress | 0.99 | 1.01 | 0.94 | 0.56 | 0.41 | 0.08 |
| Investments | 0.08 | 0.07 | 0.07 | 2.02 | 0.14 | 0.09 |
| Inventories | 0.73 | 0.53 | 0.28 | 0.14 | 0.16 | 0.09 |
| Sundry debtors | 1.85 | 1.54 | 0.60 | 0.49 | 0.36 | 0.56 |
| Cash & bank balances | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Loans & advances | 2.72 | 2.32 | 1.12 | 0.55 | 0.76 | 0.66 |
| Total current assets | 7.36 | 7.46 | 2.70 | 1.96 | 1.38 | 1.63 |
| Total current liabilities | 1.05 | 1.81 | 1.00 | 1.01 | 0.83 | 0.71 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 | 0.28 |
| Net cash from operating activities | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Net cash from investing activities | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Net cash from financing activities | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
| Net change in cash | (1.01) | 2.37 | (0.08) | 0.68 | (0.22) | 0.04 |
| Closing cash | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA growth | +22.0% | -18.0% | -26.5% | +28.3% | +27.7% | - |
| PBT growth | +13.0% | +5.9% | -40.7% | +24.6% | +27.8% | +9997.0% |
| Net income growth | +48.3% | -21.6% | -39.3% | +22.0% | +35.1% | - |
| Revenue CAGR (3Y) | +14.3% | +8.9% | +12.0% | - | - | - |
| EBITDA CAGR (3Y) | -9.7% | -8.2% | +6.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +4.5% | +4.6% | +5.9% | +9.6% | +7.8% | +8.8% |
| Return on capital employed | +7.1% | +7.9% | +12.3% | +23.6% | +31.2% | +30.7% |
| Return on net worth | +4.7% | +4.9% | +12.5% | +28.8% | +31.5% | +28.8% |
| Debt / equity | 0.02 | 0.07 | 0.32 | 0.45 | 0.44 | 0.38 |
| Long-term debt / equity | 0.02 | 0.02 | 0.09 | 0.15 | 0.26 | 0.34 |
| Interest cover | 14.29 | 16.22 | 16.07 | 7.69 | 8.82 | 13.79 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.69 | 1.68 | 1.58 | 1.77 | 2.14 | 1.86 |
| Inventory turnover | 15.05 | 20.32 | 30.48 | 42.33 | 51.04 | 50.56 |
| Debtors turnover | 5.59 | 7.69 | 11.74 | 14.94 | 13.87 | 8.13 |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 40.54 | 38.69 | 21.12 | 15.87 | 12.32 | 20.86 |
Charges & Borrowings of Clinitech Laboratory Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Feb 2026 | Others | ₹22.5 Lakh | Open |
| 09 Apr 2025 | Others | ₹20 Lakh | Open |
| 28 Dec 2021 | Others | ₹90 Lakh | Open |
| 17 Feb 2016 | Others | ₹24 Lakh | Satisfied |
| 22 Feb 2012 | Corporation Bank | ₹8 Lakh | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Clinitech Laboratory Limited
Employment history and EPFO contributions of people linked to Clinitech Laboratory.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Clinitech Laboratory Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Clinitech Laboratory Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Clinitech Laboratory Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Clinitech Laboratory Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Clinitech Laboratory Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Clinitech Laboratory Limited
Frequently Asked Questions about Clinitech Laboratory Limited
Clinitech Laboratory is an active public limited company based in Navi Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 19 March 2010 (16+ years old) and is registered under CIN L85195MH2010PLC201078.
Clinitech Laboratory reported revenue of ₹9.49 Cr for FY 2025-26 (up 15.3% YoY) based on consolidated financials.
Clinitech Laboratory has 6 current directors:
- Jagdish Umakant Nayak - Managing Director
- Jyoti Jagdish Nayak - Whole-Time Director
- Ravikant Moreshwar Mhatre - Director
- Balu Laxman Kumbharkar - Director
- Ashutosh Jagdish Nayak - Director
- Smita Arjun Patil - Director
The CIN (Corporate Identification Number) of Clinitech Laboratory is L85195MH2010PLC201078. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes, Clinitech Laboratory is a listed company.
Clinitech Laboratory was incorporated on 19 March 2010, making it 16+ years old. It is registered with the Registrar of Companies, Mumbai.
Clinitech Laboratory can be reached through the website ctllab.in. Its registered office is in Navi Mumbai, Maharashtra, India.
The registered office of Clinitech Laboratory is at Al – 1545 Sector 16 Airoli Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Maharashtra, India – 400708.
Clinitech Laboratory has an authorised share capital of ₹5 Cr and a paid-up capital of ₹2.28 Cr.